The investigation centers on the company’s bitopertin program. On February 13, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine, effectively denying the approval of its new drug application. Federal regulators cited significant uncertainties in the application that required additional evidence, a disclosure that caused the company's stock to plummet 22% in a single day.

Rosen Law Firm, which specializes in shareholder derivative litigation, is soliciting participants for a prospective class action. Investors who purchased securities during the relevant period may be eligible for compensation under a contingency fee arrangement. Those interested in the inquiry are directed to reach out to attorney Phillip Kim to discuss potential recovery options for their financial losses.